Определение механизма сопутствующей противовоспалительной активности у нового противосудорожного агента - производного пиразолопиримидина

Abstract

Based on the results of affinity prediction and detailed analysis of conformational placement and interaction with amino acid residues of active sites, the mechanism of realization of anti-inflammatory effect of 1-(4-methoxyphenyl)-5-(2-(4-(4-methoxyphenyl)piperazine-1-yl)-2-oxo-ethyl)pyrazol[3,4-d]pyrimidine-4-one as cyclooxygenase 2 inhibitor through site-selective inhibitor of celecoxib was established.